Citation Report
List of articles citing

Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)

DOI: 10.1111/1759-7714.13328
Thoracic Cancer, 2020, 11, 511-518.

#	Paper	IF	Citations
183	Knockdown of circPRKCA Restrained Cell Growth, Migration, and Invasion of NSCLC Cells Both in vitro and in vivo via Regulating miR-330-5p/PDK1/AKT Pathway. **2020**, 12, 9125-9137		4
182	Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. **2020**, 12, 1758835920953728		6
181	Long non-coding RNA TRPM2-AS sponges microRNA-138-5p to activate epidermal growth factor receptor and PI3K/AKT signaling in non-small cell lung cancer. **2020**, 8, 1313		11
180	Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma. **2020**, 2020, 8024138		2
179	UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target. **2020**, 20, 824		4
178	CPA4 Promotes EMT in Pancreatic Cancer via Stimulating PI3K-AKT-mTOR Signaling. **2020**, 13, 8567-8580		7
177	Astaxanthin targets PI3K/Akt signaling pathway toward potential therapeutic applications. **2020**, 145, 111714		23
176	Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy. *Cancers*, **2020**, 12,	6.6	11
175	Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway. **2021**, 12, 76-88		12
174	Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer. **2021**, 22, e98-e111		3
173	Yang-Yin-Jie-Du decoction overcomes gefitinib resistance in non-small cell lung cancer via down-regulation of the PI3K/Akt signalling pathway. **2021**, 59, 1294-1304		
172	A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma. **2021**, 12, 5932-5949		13
171	Silencing of SmgGDS, a Novel mTORC1 Inducer That Binds to RHEBs, Inhibits Malignant Mesothelioma Cell Proliferation. **2021**, 19, 921-931		0
170	TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β/catenin/Snail axis. **2021**, 10, 936-954		3
169	Concealed driver in lung adenocarcinoma with single PIK3CA mutation: a case report and single-center genotyping review. **2021**, 9, 271		0
168	mTOR Signaling in Pulmonary Vascular Disease: Pathogenic Role and Therapeutic Target. **2021**, 22,		8
167	Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma. **2021**,		2

166	Marine-Derived Natural Products as ATP-Competitive mTOR Kinase Inhibitors for Cancer Therapeutics. **2021**, 14,		8
165	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. **2021**, 22,		9
164	Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer. **2021**, 11, 645475		7
163	Identification of Novel MicroRNAs Targeting SARS-CoV-2 through the Regulation of TMPRSS2/PI3K/AKT/PTEN Alignment in Lung Cancer: An Analysis. **2021**, 4, 1075-1078		1
162	Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review. **2021**, 9, 621		11
161	AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth. *Cell Death and Disease*, **2021**, 12, 365	9.8	6
160	Qiyusanlong Formula Induces Autophagy in Non-Small-Cell Lung Cancer Cells and Xenografts through the mTOR Signaling Pathway. *Evidence-based Complementary and Alternative Medicine*, **2021**, 2021, 5575453	2.3	
159	HIV-negative case of pulmonary infection with a mutation. **2021**, 49, 3000605211016761		1
158	Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data. **2021**, 2021, 8817898		1
157	AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review. *Cancers*, **2021**, 13,	6.6	2
156	GTSE1 Facilitates the Malignant Phenotype of Lung Cancer Cells via Activating AKT/mTOR Signaling. **2021**, 2021, 5589532		0
155	The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620. **2021**, 11, 669518		2
154	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision. **2021**, 180, 739-752		4
153	Targeted Therapies in Lung Cancers: Current Landscape and Future Prospects. **2021**,		0
152	Comparison of COVID-19 and Lung Cancer Reactive Oxygen Species Signaling. **2021**, 11, 708263		0
151	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. **2021**, 6, 254		30
150	Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling. **2021**, 21, 338		2
149	Pyronaridine induces apoptosis in non-small cell lung cancer cells by upregulating death receptor 5 expression and inhibiting epidermal growth factor receptor. **2021**,		1

148	Sodium Danshensu inhibits the progression of lung cancer by regulating PI3K/Akt signaling pathway. **2021**,		0
147	Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways. *Evidence-based Complementary and Alternative Medicine*, **2021**, 2021, 5517143	2.3	0
146	The requirement of mitochondrial RNA polymerase for non-small cell lung cancer cell growth. *Cell Death and Disease*, **2021**, 12, 751	9.8	6
145	Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis. *Oncotarget*, **2021**, 12, 1470-1489	3.3	6
144	Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway. **2021**, 19, 232		4
143	Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles. **2021**, 21, 939		0
142	Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway. **2021**, 2021, 9950663		1
141	Identification of Ent-Kaurane Diterpenoid Compounds as Potential Inhibitors of the PI3K Pathway in Nonsmall Cell Lung Cancer Through Molecular Docking Simulations. **2021**, 16, 1934578X2110332		
140	The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer. **2021**, 22,		1
139	Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer. **2021**, 285, 119984		6
138	Synthesis and Biological Evaluation of ()-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells. **2021**, 14,		1
137	Dysregulation of cholesterol homeostasis in human lung cancer tissue and tumour-associated macrophages. **2021**, 72, 103578		6
136	Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. **2021**, 64, 14603-14619		2
135	DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p. **2021**, 123, 151788		3
134	Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells. **2021**, 142, 111961		1
133	Profiling and Integrated Analysis of Differentially Expressed Circular RNAs in Plasma Exosomes as Novel Biomarkers for Advanced-Stage Lung Adenocarcinoma. **2020**, 13, 12965-12977		6
132	H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation.. **2022**, 28, e933447		
131	Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma. **2021**,		7

130	UBR-Box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.	
129	Muyin extract inhibits non-small-cell lung cancer growth by inducing autophagy and apoptosis in vitro and in vivo.. **2021**, 96, 153834	1
128	Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma.	
127	EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. **2022**, 524, 151-160	1
126	The mTOR Pathway in Pluripotent Stem Cells: Lessons for Understanding Cancer Cell Dormancy. **2021**, 11,	0
125	Liquid biopsy: Novel perspectives on the importance and spectrum of , and mutations in solid tumors. **2022**, 16, 1	
124	Molecular cytogenetic characterization of the urethane-induced murine lung cell line LA-4 as a model for human squamous cell lung cancer. **2022**, 16, 9	
123	CircRPPH1 promotes cell proliferation, migration and invasion of non-small cell lung cancer (NSCLC) via the PI3K/AKT and JAK2/STAT3 signaling axes. **2021**,	0
122	Microarray Identifies a Key Carcinogenic Circular RNA 0008594 That Is Related to Non-Small-Cell Lung Cancer Development and Lymph Node Metastasis and Promotes NSCLC Progression by Regulating the miR-760-Mediated PI3K/AKT and MEK/ERK Pathways. **2021**, 11, 757541	2
121	Identification of an Immune-Related Biomarker Model Based on the CircRNA-Associated Regulatory Network for Esophageal Carcinoma. **2021**, 2021, 1334571	0
120	Prediction of Genes Involved in Lung Cancer with a Systems Biology Approach Based on Comprehensive Gene Information. **2021**, 1	1
119	Ultrasound-targeted microbubble destruction mediated miR-492 inhibitor suppresses the tumorigenesis in non-small cell lung cancer. **2021**, 53, 2246-2255	2
118	Effect of Chemotherapy on Immune Factors in Patients with Non-Small Cell Lung Cancer. **2021**, 09, 110-117	
117	The circ-PITX1 promotes non-small cell lung cancer development via the miR-30e-5p/ITGA6 axis.. **2022**, 1-18	0
116	Therapeutic benefits of species: A focus on cancer and viral infection.. **2022**, 8, e08763	0
115	Circ_0017639 facilitates proliferative, migratory, and invasive potential of non-small cell lung cancer (NSCLC) cells via PI3K/AKT signaling pathway.. **2022**, 13, 1590-1601	2
114	Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis.. **2022**, 17, e0261464	2
113	Targeting KRAS mutant lung cancer: light at the end of the tunnel.. **2021**,	1

112	Network Pharmacology Integrated with Molecular Docking Reveals the Mechanism of Xiben Pills Against NSCLC.		
111	The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting to Elucidate the Synergistic Pathway of Survivin with P-Glycoprotein in Cancer Multi-Drug Resistance.. **2021**, 9, 797005		
110	Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.. *Cell Death and Disease*, **2022**, 13, 129	9.8	2
109	Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: association with immunomodulation.. **2022**,		1
108	The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles.. **2022**, 18, 101364		4
107	Biology and pathophysiology of central nervous system metastases. **2022**, 55-78		
106	Intrinsic and Extrinsic Factors Impacting Cancer Stemness and Tumor Progression.. *Cancers*, **2022**, 14,	6.6	3
105	Polyacetylenes from Root Induced Apoptosis of Human Lung Adenocarcinoma Cells and Improved Lung Dysbiosis.. **2022**, 2022, 7713355		0
104	Akt/mTOR Activation in Lung Cancer Tumorigenic Regulators and Their Potential Value as Biomarkers. **2022**, 2, 36-55		
103	5--(-Boc-l-Alanine)-Renieramycin T Induces Cancer Stem Cell Apoptosis via Targeting Akt Signaling.. **2022**, 20,		2
102	Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.. **2022**, 13, 7197-7208		1
101	In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer.		
100	Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer Integrating Network Pharmacology and Experimental Validation and .. **2021**, 12, 791269		0
99	Low-Temperature Plasma-Activated Medium Inhibited Proliferation and Progression of Lung Cancer by Targeting the PI3K/Akt and MAPK Pathways.. **2022**, 2022, 9014501		
98	Small cell lung cancer transformation: From pathogenesis to treatment.. **2022**,		2
97	Systematic Analysis of Stress Granule Regulators-Associated Molecular Subtypes Predicts Drug Response, Immune Response, and Prognosis in Non-Small Cell Lung Cancer.. **2022**, 10, 868918		0
96	Targeting lncRNAs in programmed cell death as a therapeutic strategy for non-small cell lung cancer.. *Cell Death Discovery*, **2022**, 8, 159	6.9	1
95	Combined metabolomics with transcriptomics reveals potential plasma biomarkers correlated with non-small-cell lung cancer proliferation through the At pathway.. **2022**,		0

94	The mechanism of dioscin preventing lung cancer based on network pharmacology and experimental validation.. **2022**, 115138		0
93	Electronic, spectroscopic, molecular docking and molecular dynamics studies of neutral and zwitterionic forms of 3, 4-dihydroxy-l-phenylalanine: A novel lung cancer drug. **2022**, 1260, 132844		2
92	Integrative RNA-Seq and ATAC-Seq Analysis Reveals the Migration-Associated Genes Involved in Antitumor Effects of Herbal Medicine Feiyanning on Lung Cancer Cells.. **2021**, 12, 799099		1
91	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. **2021**, 2, 692-729		2
90	Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.. *Cancers*, **2021**, 13,	6.6	2
89	Signaling Pathway Inhibitors, miRNA, and Nanocarrier-Based Pharmacotherapeutics for the Treatment of Lung Cancer: A Review.. **2021**, 13,		0
88	3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.		
87	PI3K/Akt/mTOR pathways inhibitors with potential prospects in non-small cell lung cancer. *Journal of Environmental Pathology, Toxicology and Oncology*, **2022**,	2.1	0
86	Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways.. **2022**, 23, 170		0
85	METTL3 Promotes the Progression of Lung Cancer via Activating PI3K/AKT/mTOR Pathway.. **2022**,		0
84	MiR-1306-5p predicts favorable prognosis and inhibits proliferation, migration, and invasion of colorectal cancer cells via PI3K/AKT/mTOR pathway.. **2022**, 1-11		1
83	[Naphthalene allyl trifluoromethyl benzocyclopentanone inhibits proliferation and induces apoptosis of lung cancer A549 cells].. *Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University*, **2022**, 42, 201-206	0.5	
82	ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway. *Tissue and Cell*, **2022**, 101817	2.7	0
81	Impacts of Oxidative Stress and PI3K/AKT/mTOR on Metabolism and the Future Direction of Investigating Fucoidan-Modulated Metabolism. *Antioxidants*, **2022**, 11, 911	7.1	3
80	Chemotolerance of Breast Cancer and Its Management by Personalized Medicine. **2022**, 403-417		
79	Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model. *Computational and Mathematical Methods in Medicine*, **2022**, 2022, 1-9	2.8	1
78	An insight on PI3K/AKT/MTOR inhibitors in cancer: Opportunity and translational perspectives. **2022**, 97-127		
77	When "No-Smoking" is not enough: Hypoxia and nicotine acetylcholine receptor signaling may drive lung adenocarcinoma progression in never-smokers. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2022**, 119302	4.9	

76	Deciphering miR-520c-3p as a probable target for immunometabolism in non-small cell lung cancer using systems biology approach. *Oncotarget*, **2022**, 13, 725-746	3.3	0
75	Recent developments and challenges in the molecular targeted therapies of non-small cell lung cancer. *Journal of Environmental Pathology, Toxicology and Oncology*, **2022**,	2.1	0
74	Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives. *Cancers*, **2022**, 14, 2829	6.6	2
73	Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer. *Cancer Medicine*,	4.8	0
72	Inhibition of mTORC1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. *Molecular Cancer Therapeutics*,	6.1	
71	An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth. *Cell Death Discovery*, **2022**, 8,	6.9	0
70	The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth. *Cell Death and Disease*, **2022**, 13,	9.8	0
69	Ginsenoside Rg1 Suppresses Non-Small-Cell Lung Cancer via MicroRNA-126-PI3K-AKT-mTOR Pathway. *Evidence-based Complementary and Alternative Medicine*, **2022**, 2022, 1-12	2.3	1
68	DriverRWH: discovering cancer driver genes by random walk on a gene mutation hypergraph. *BMC Bioinformatics*, **2022**, 23,	3.6	0
67	The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications. *Drug Resistance Updates*, **2022**, 63, 100852	23.2	3
66	Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth. *Cell Death and Disease*, **2022**, 13,	9.8	0
65	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. *Cancers*, **2022**, 14, 3337	6.6	2
64	Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases. *Acta Pharmaceutica Sinica B*, **2022**,	15.5	1
63	Molecular docking and dynamics based approach for the identification of kinase inhibitors targeting PI3K against non-small cell lung cancer: a computational study. **2022**, 12, 21452-21467		3
62	WWP2 overexpression inhibits the antitumor effects of doxorubicin in hepatocellular carcinoma.		
61	Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. **2022**, 12,		2
60	Sheep tail fat inhibits the proliferation of non-small-cell lung cancer cells in vitro and in vivo. 13,		
59	Molecular mechanism of Rhubarb in the treatment of non-small cell lung cancer based on network pharmacology and molecular docking technology.		

58	AKT phosphorylation as a predictive biomarker for PI3K/mTOR dual inhibition-induced proteolytic cleavage of mTOR companion proteins in small cell lung cancer. **2022**, 12,	
57	Can aloin develop to medicines or healthcare products?. **2022**, 153, 113421	0
56	Research progress of bone-targeted drug delivery system on metastatic bone tumors. **2022**, 350, 377-388	0
55	Targeted Therapies in Non-small Cell Lung Cancer. **2022**,	1
54	Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: A review. **2023**, 300, 115748	3
53	The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer. **2022**, 27,	0
52	Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. 12,	1
51	Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects. **2022**, 23, 10132	1
50	Bioinformatics identification of miR-514b-5p promotes NSCLC progression and induces PI3K/AKT and p38 pathways by targeting small glutamine-rich tetratricopeptide repeat-containing protein beta.	0
49	Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways. **2022**, 103865	0
48	Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. **2022**, 3,	1
47	The regulatory role of PDE4B in the progression of inflammatory function study. 13,	1
46	Silencing of CPSF7 inhibits the proliferation, migration, and invasion of lung adenocarcinoma cells by blocking the AKT/mTOR signaling pathway. **2022**, 17, 1655-1663	0
45	Quantification of promoting efficiency and reducing toxicity of Traditional Chinese Medicine: A case study of the combination of Tripterygium wilfordii hook. f. and Lysimachia christinae hance in the treatment of lung cancer. 13,	0
44	A Connexin-Based Biomarker Model Applicable for Prognosis and Immune Landscape Assessment in Lung Adenocarcinoma. **2022**, 2022, 1-12	0
43	AKBA inhibits radiotherapy resistance in lung cancer by inhibiting maspin methylation and regulating the AKT/FOXO1/p21 axis.	0
42	An in silico comparative transcriptome analysis identifying hub lncRNAs and mRNAs in brain metastatic small cell lung cancer (SCLC). **2022**, 12,	0
41	Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models. 12,	0

40	WDR72 Enhances the Stemness of Lung Cancer Cells by Activating the AKT/HIF-1 Signaling Pathway. **2022**, 2022, 1-12	1
39	Exosome-transmitted S100A4 induces immunosuppression and non-small cell lung cancer development by activating STAT3.	0
38	Selenium-binding protein 1 inhibits malignant progression and induces apoptosis via distinct mechanisms in non-small-cell lung cancer.	2
37	Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.	1
36	Metabolic reprogramming in the immunosuppression of tumor-associated macrophages. Publish Ahead of Print,	0
35	Explore the mechanism and substance basis of Mahuang FuziXixin Decoction for the treatment of lung cancer based on network pharmacology and molecular docking. **2022**, 151, 106293	0
34	Molecular recognition of some novel mTOR kinase inhibitors to develop anticancer leads by drug-likeness, molecular docking and molecular dynamics based virtual screening strategy. **2023**, 25, 100257	0
33	Targeting the DNA Damage Response Machinery for Lung Cancer Treatment. **2022**, 15, 1475	0
32	Anwuligan inhibits the progression of non-small cell lung cancer via let-7c-3p/PI3K/AKT/mTOR axis.	0
31	Evaluating the Expression and Prognostic Value of Genes Encoding Microtubule-Associated Proteins in Lung Cancer. **2022**, 23, 14724	0
30	Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions. **2022**, 65, 16033-16061	2
29	MicroRNA-340 and MicroRNA-450b-5p: Plasma Biomarkers for Detection of Non-Small-Cell Lung Cancer. **2022**, 2022, 1-8	0
28	Phosphorylation of PBX2, a novel downstream target of mTORC1, is determined by GSK3 and PP1.	0
27	The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer. **2022**, 28, 3563-3571	0
26	N,N?-Diarylurea Derivatives (CTPPU) Inhibited NSCLC Cell Growth and Induced Cell Cycle Arrest through Akt/GSK-3 c-Myc Signaling Pathway. **2023**, 24, 1357	0
25	Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models. 12,	0
24	Ribosomal protein L22-like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway.	0
23	The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis. **2022**, 101, e32340	0

22	Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.	0
21	Scopoletin: Anticancer potential and mechanism of action. **2023**, 13, 1	0
20	Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer. 13,	0
19	Construction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma. **2023**, 15, 2293-2307	0
18	USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway. **2023**, 18,	0
17	Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer models. **2023**, 378, 110467	0
16	Unraveling the Post-Translational Modifications and therapeutical approach in NSCLC pathogenesis. **2023**, 33, 101673	0
15	TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment. **2023**, 2023, 1-17	0
14	Repressing IRS1 /2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K / AKT / mTOR pathway and inducing autophagy. **2023**, 39, 377-389	0
13	Ginsenoside Rg3 enhances the radiosensitivity of lung cancer A549 and H1299 cells via the PI3K/AKT signaling pathway. **2023**, 59, 19-30	0
12	Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. **2023**, 12, 1711	0
11	Inhibition of apoptosis through AKT-mTOR pathway in ovarian cancer and renal cancer.	0
10	Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. **2023**, 178, 229-236	0
9	Addition of metformin for non-small cell lung cancer patients receiving antineoplastic agents. 14,	0
8	The role of selected non-coding RNAs in the biology of non-small cell lung cancer. **2023**, 68, 121-137	0
7	HNRNPD is a prognostic biomarker in non-small cell lung cancer and affects tumor growth and metastasis via the PI3K-AKT pathway. 1-20	0
6	Effects of saponins from Chinese herbal medicines on signal transduction pathways in cancer: A review. 14,	0
5	Curcumin and Plumbagin Synergistically Target the PI3K/Akt/mTOR Pathway: A Prospective Role in Cancer Treatment. **2023**, 24, 6651	0

4	Raddeanin A promotes autophagy-induced apoptosis by inactivating PI3K/AKT/mTOR pathway in lung adenocarcinoma cells.	0
3	A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer. **2023**, 40,	0
2	Meta-analysis of commonly mutated genes in leptomeningeal carcinomatosis. 11, e15250	0
1	Computational drug repurposing of Akt-1 allosteric inhibitors for non-small cell lung cancer. **2023**, 13,	0